Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Scancell Holdings's share price for the quarter that ended in Oct. 2023 was £0.123701. Scancell Holdings's Shares Outstanding (EOP) for the quarter that ended in Oct. 2023 was 819.98 Mil. Therefore, Scancell Holdings's market cap for the quarter that ended in Oct. 2023 was £101.43 Mil.
Scancell Holdings's quarterly market cap
declined
from Oct. 2022 (£137.08 Mil) to Apr. 2023 (£128.16 Mil) and
declined
from Apr. 2023 (£128.16 Mil) to Oct. 2023 (£101.43 Mil).
Scancell Holdings's annual market cap
declined
from Apr. 2021 (£179.35 Mil) to Apr. 2022 (£116.17 Mil) but then
increased
from Apr. 2022 (£116.17 Mil) to Apr. 2023 (£128.16 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Scancell Holdings's Enterprise Value for Today is £91.74 Mil.
Scancell Holdings Market Cap Historical Data
The historical data trend for Scancell Holdings's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Scancell Holdings's Market Cap
For the Biotechnology subindustry, Scancell Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's Market Cap falls into.
Scancell Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Scancell Holdings's Market Cap for the fiscal year that ended in Apr. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (LSE:SCLP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Scancell Holdings Market Cap Related Terms
Thank you for viewing the detailed overview of Scancell Holdings's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:SCLP has been successfully added to your 